Stock analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research note issued on Wednesday. The firm set a “hold” rating on the stock.
TherapeuticsMD Stock Performance
TXMD opened at $1.78 on Wednesday. The stock’s fifty day simple moving average is $1.74 and its 200 day simple moving average is $1.99. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $3.82.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $0.23 million for the quarter.
Hedge Funds Weigh In On TherapeuticsMD
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Recommended Stories
- Five stocks we like better than TherapeuticsMD
- 10 Best Airline Stocks to Buy
- Emerging Markets: What They Are and Why They Matter
- What is Short Interest? How to Use It
- Recession or Not, These 3 Stocks Are Winners
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.